# US 2023/0414500 A1 · Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414500 A1
- Document ID: US20230414500A1
- Status: Published application
- Kind: A1
- Application number: 18/367,118
- Filed: 2023-09-12
- Published: 2023-12-28
- Earliest claimed: 2006-02-22
- Assignees: MannKind Corporation
- Applicants: MannKind Corporation
- Inventors: Bryan R. Wilson; Marshall Grant
- Web page: https://patentgrep.com/patent/US20230414500A1

## CPC

- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/145: {with organic compounds}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 38/28: Insulins
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.

## Claims

### Claim 1

A process for manufacturing a crystalline microparticle of a diketopiperazine loaded with an active agent wherein the diketopiperazine has the formula of 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is a succinyl, glutaryl, maleyl, or fumaryl group comprising the steps of: adding the diketopiperazine in a to water to form an aqueous suspension, maintaining the diketopiperazone solution at a controlled temperature between about 15° C. to about 18° C., adding the active agent to water to form an aqueous solution or suspension of the active, mixing the diketopiperazine aqueous suspension with the active agent aqueous solution or suspension, and then spray-drying the admixture to remove solvent, using a spray dryer having an inlet and outlet, to form a spray-dried powder.

### Claim 2 (depends on 1)

The process of claim 1, wherein the inlet of the spray dryer has a temperature of between, or equal, to 105° C. to 140° C.

### Claim 4 (depends on 1)

The process of claim 1, wherein the spray dryer produces an atomization pressure of between, or equal, to 0.4 to 1.1 bar.

### Claim 5 (depends on 1)

The process of claim 1, wherein the spray dryer produces a spray rate of between, or equal to, 4.4 to 12.2 g/min.

### Claim 6 (depends on 1)

The process of claim 1, wherein the spray dryer produces a spray-dried powder of between, or equal to, 0.150 to 0.200 g/cc.

### Claim 7 (depends on 1)

The process of claim 1, wherein the spray dryer produces a spray-dried powder that has a tap density of between, or equal to, 0.250 to 0.300 g/cc.

### Claim 8 (depends on 1)

The process of claim 1, wherein the active agent is insulin.

### Claim 9 (depends on 8)

The process of claim 8, wherein the spray-dried powder has an insulin content of about 3% to about 50% by weight.

### Claim 10 (depends on 1)

The process of claim 1, wherein the active agent is selected from the group consisting of: insulin, calcitonin, parathyroid hormone 1-34, or other bioactive fragment of parathyroid hormone, octreotide, leuprolide, and RSV peptide, felbamate, cannabinoid antagonists and/or agonists, muscarinic antagonists and/or agonists, heparin, low molecular weight heparin, cromolyn, sildenafil, vardenafil, tadalafil growth hormone, zidovudine (AZT), didanosine (DDI), granulocyte-colony stimulating factor (GCSF), lamotrigine, chorionic gonadotropin releasing factor, luteinizing release hormone, β-galactosidase, GLP-1, exendins 1-4, ghrelin, and fragments thereof.
